Kintara Therapeutics Inc (NASDAQ: KTRA) announced topline data consequences from the recurring support of its open-label, Stage 2 scientific study of its lead compound VAL-083 being led at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Stage 2 pilot is a two-arm, biomarker-driven education The Stage 2 […]